AN2 Therapeutics(US:ANTX)2024-03-28 20:15Financial Performance - Cash, cash equivalents, and investments totaled $134.5 million as of December 31, 2023[1] - Research and Development (R&D) expenses for the full year 2023 were $54.9 million, up from $29.5 million in 2022, with Q4 2023 R&D expenses at $14.9 million compared to $8.8 million in Q4 2022[6] - General and Administrative (G&A) expenses for the full year 2023 were $14.8 million, compared to $12.8 million in 2022, with Q4 2023 G&A expenses at $3.9 million versus $3.7 million in Q4 2022[6] - Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in 2022, with a Q4 2023 net loss of $16.9 million compared to $11.8 million in Q4 2022[7] Clinical Trials and Research - The Phase 2 topline results for the epetraborole trial in treatment-refractory Mycobacterium avium Complex (TR-MAC) are expected in summer 2024[1] - The Phase 3 enrollment for the epetraborole trial is currently paused due to an analysis showing potentially lower than expected efficacy, with 97 patients enrolled[3] - A licensing agreement was signed with the University of Georgia Research Foundation to develop a novel therapy for chronic Chagas disease, which is in late preclinical development[2] - The company received a grant from the Bill & Melinda Gates Foundation to discover novel boron-containing small molecules for tuberculosis and malaria treatment[5] - The company plans to discuss the Phase 2/3 trial data with the FDA in the coming months[2] - The company presented new epetraborole data at the IDWeek 2023 conference, highlighting its potential in treating NTM lung disease[4]